Cholesteryl ester transfer protein in metabolic syndrome

Obesity

Volumn 14, Issue 5, 2006, Pages 812-818

  Sandkofer, Anton ^a   Kaser, Susanne ^a   Ritsch, Andreas ^a   Laimer, Markus ^a   Engl, Julia ^a   Paulweber, Bernhard ^b   Patsch, Josef R ^a   Ebenbichler, Christoph F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b St Johannes Spital   (Austria)

Author keywords

Cholesteryl ester transfer protein; High density lipoprotein cholesterol; Metabolic syndrome; Small dense low density lipoprotein

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CHEMISTRY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PARTICLE SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE; WAIST HIP RATIO;

ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PARTICLE SIZE; SEX FACTORS; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 33846078995     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2006.94     Document Type: Article

References (40)

1. Third Report of the National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.
3. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-21.
5. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20:2140-7.
6. Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol. 1999;10:321-7.
7. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 1993;13:815-25.
8. Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb. 1994;14:1129-36.
9. Ebenbichler CF, Laimer M, Kaser S, et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol. 2002;22:1465-9.
10. Esterbauer H, Schneitier C, Oberkofler H, et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 2001;28:178-83.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.
13. Ritsch A, Ebenbichler C, Naschberger E, et al. Phagedisplayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med. 2004;42:247-55.
14. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24:e13-8.
15. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol. 2005;25:553-9.
16. Hulthe J, Wiklund O, Bondjers G, Wikstrand J. LDL particle size in relation to intima-media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia. J Intern Med. 2000;248:42-52.
17. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
18. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-91.
19. Brewer HB Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:387-91.
20. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-72.
21. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285-8.
22. Ritsch A, Patsch JR. Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr Opin Lipidol. 2003;14:173-9.
23. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111:278-87.
24. Guerin M, Le Goff W, Lassel TS, Van Toi A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21:282- 8.
25. Guerin M, Egger P, Soudant C, et al. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the post-prandial state. J Lipid Res. 2002;43:1652-60.
26. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991;88:2059-66.
27. Foger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:1430-6.
28. Riemens S, van Toi A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis. 1998;140:71-9.
29. Hogue JC, Lamarche B, Gaudet D, et al. Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J Lipid Res. 2004;45:1077-83.
30. Ritsch A, Drexel H, Amann FW, Pfeifhofer C, Patsch JR. Deficiency of cholesteryl ester transfer protein: description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol. 1997;17:3433-41.
31. Bisgaier CL, Siebenkas MV, Brown ML, et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin, J Lipid Res. 1991;32:21-33.
32. Sakai N, Matsuzawa Y, Hirano K, et al. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb. 1991;11:71-9.
33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:e149-61.
34. Maumus S, Marie B, Siest G, Visvikis-Siest S. A Prospec-tive Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-{alpha}) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care. 2005;28:675-82.
35. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-60.
36. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-15.
37. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-7.
38. Okamoto H, Iwamoto Y, Maki M, Sotani T, Yonemori F, Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol. 2003;466:147-54.
39. Zhang B, Fan P, Shimoji E, et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol. 2004;24:1910-5.
40. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta. 2000;1500:88-96.